SPRYARS Pharmaceuticals, Inc.
Pharmaceutical Preparations
- Revenue
- $84M
- 5.5% YoY
- Operating margin
- -212.9%
- 6057% YoY
- EBITDA
- −$178M
- 5828% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $89M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired26% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $6M | $1M | $30K | $89M | $84M | 5.5% |
| Operating income | −$19M | −$36M | −$68M | −$3M | −$179M | 5721% |
| Net income | −$20M | −$35M | −$54M | $8M | −$171M | 2242% |
| Operating cash flow | −$18M | −$40M | −$59M | $14M | −$171M | 1361% |
| Capex | $55K | $199K | $175K | $563K | $339K | 40% |
| Stock-based comp | $3M | $6M | $9M | $15M | $22M | 52% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $10M | $10M | 213 | — |
| FY2024 | $7M | $15M | 193 | — |